Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

Bruce A. Perkins, Nima Soleymanlou, Julio Rosenstock, Jay S. Skyler, Lori M. Laffel, Karl Heinz Liesenfeld, Dietmar Neubacher, Matthew M. Riggs, Curtis K. Johnston, Rena J. Eudy-Byrne, Ahmed Elmokadem, Jyothis T. George, Jan Marquard, Valerie Nock

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint Dive into the research topics of 'Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy'. Together they form a unique fingerprint.

Medicine & Life Sciences